<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908076</url>
  </required_header>
  <id_info>
    <org_study_id>H-21192</org_study_id>
    <nct_id>NCT00908076</nct_id>
    <nct_alias>NCT00849784</nct_alias>
  </id_info>
  <brief_title>Amitiza in Constipation Associated With PD (Parkinson's Disease)</brief_title>
  <acronym>AMITIZA</acronym>
  <official_title>Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Amitiza (lubiprostone), a drug proven to be safe&#xD;
      and effective for chronic constipation, will also improve constipation symptoms in&#xD;
      Parkinson's Disease patients. We will also evaluate the impact of the drug on changes in&#xD;
      bowel movement consistency, quality of life and motor symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) affects about one million people in the United States. It is a&#xD;
      common neurological condition that is clinically defined by rigidity (muscle stiffness),&#xD;
      bradykinesia (slowness of movement) and tremor. Parkinson's Disease , however, reveals&#xD;
      numerous non-motor symptoms that have been underemphasized. Problematic symptoms include&#xD;
      varying degrees of dementia, psychosis, diminished assertiveness and confidence, general&#xD;
      fatigue, excessive daytime sleepiness, problems with blood pressure, sweating, and bladder,&#xD;
      and a common yet difficult to define sense of &quot;not feeling well&quot;.&#xD;
&#xD;
      A commonly missed symptom in Parkinson's patients is constipation. Constipation can be&#xD;
      difficult to treat with current medications available and many are ineffective. Levodopa and&#xD;
      dopamine agonists drugs are useful for motor symptoms in Parkinson's Disease but have no&#xD;
      effect on constipation. Laxatives and enemas provide limited relief with bothersome side&#xD;
      effects. Even fewer drugs have been studied targeting the constipation problem specifically&#xD;
      in the Parkinson's Disease population. Lubiprostone (AMITIZA) is a new medication that has&#xD;
      been studied in the general population for the treatment of chronic constipation. It has been&#xD;
      shown to be a safe and effective medication with few side effects. Lubiprostone has not yet&#xD;
      been studied in the Parkinson's Disease population. We hope to show that this medication can&#xD;
      be safe and effective for constipation in PD patients as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Study</measure>
    <time_frame>Baseline to end of study</time_frame>
    <description>Global impression of change, stool diary, visual analog scale of improvement, UPDRS rating scale and constipation questionnaires. The primary efficacy data will be analyzed using Student's t-test with unequal variances as the difference from baseline in SBM comparing cases and controls, using last observation carried forward for missing data in the intent-to-treat population.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>amitiza</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amitiza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUBIPROSTONE</intervention_name>
    <description>Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>amitiza</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects must be diagnosed with PD according to conventional criteria.&#xD;
&#xD;
          -  2. Subjects must report having constipation and fulfill Rome III criteria19 for&#xD;
             chronic constipation: at least 3 months, in the last 6 months with two or more of the&#xD;
             following: i. Less than 3 SBM's per week ii. Straining with defecation more than 25%&#xD;
             of the time iii. Lumpy or hard stools with defecation more than 25% of the time iv.&#xD;
             Sensation of incomplete evacuation with defecation more than 25% of the time v.&#xD;
             Sensation of anorectal obstruction or blockage with defecation more than 25% of the&#xD;
             time vi. Use of manual maneuvers to facilitate defecation more than 25% of the time&#xD;
&#xD;
          -  3. Patients will be encouraged to use only lubiprostone for constipation. If they use&#xD;
             any other agents they will need to record this use in their diary; any BM that occurs&#xD;
             within 24 hours of the other agent used will be recorded, but not be counted as a SBM.&#xD;
&#xD;
          -  4. Patients or patients' caretaker(s)/ legal guardian must be able to read,&#xD;
             understand, and accurately record data into the diary to guarantee full participation&#xD;
             in the study.&#xD;
&#xD;
          -  5. Patients over the age of 50 must have had a colonoscopy or sigmoidoscopy within 5&#xD;
             years.&#xD;
&#xD;
          -  6. Patients or patient's caretaker(s)/legal guardian must be willing and able to&#xD;
             provide informed consent before beginning the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of structural abnormality of the gastrointestinal tract or&#xD;
             diseases/conditions that affect bowel transit including gastric, small bowel or&#xD;
             colonic resection (appendectomy, cholecystectomy, benign polypectomy are allowed);&#xD;
             history of colon cancer, history of inflammatory bowel disease (Crohn's disease or&#xD;
             ulcerative colitis); insulin-dependent diabetes mellitus, history of Hirschsprung's&#xD;
             disease, progressive systemic sclerosis (scleroderma), anorexia nervosa; other&#xD;
             diseases or conditions that in the opinion of the investigator significantly affect&#xD;
             bowel transit. Subjects with constipation secondary to any other documented cause.&#xD;
&#xD;
          -  Planned use of drugs or agents during pretreatment phase onward that affect&#xD;
             gastrointestinal motility and/ or prescription including laxatives including stool&#xD;
             softeners (patients experiencing significant constipation may use a laxative as rescue&#xD;
             medication if needed); antidiarrheals (in case of significant diarrhea loperamide may&#xD;
             be used if needed); antacids containing magnesium or aluminum salts (only calcium&#xD;
             containing ones are allowed); anticholinergics, antispasmodic agents (e.g., Librax,&#xD;
             Donnatal, dicyclomine); erythromycin and other macrolides; octreotide; ondansetron or&#xD;
             other 5-HT3 antagonists; opioids/narcotic analgesics; prokinetics (metoclopramide);&#xD;
             serotonin re-uptake inhibitors or tricyclic antidepressants (allowed if constant doses&#xD;
             for at least 1 month before treatment); calcium antagonists (allowed if constant doses&#xD;
             for at least 1 month before treatment).&#xD;
&#xD;
          -  Subjects with any significant cardiovascular, liver, lung, renal, psychiatric or&#xD;
             neurological diseases (not including PD).&#xD;
&#xD;
          -  Patients with previous allergic reaction or lack of tolerability to lubiprostone.&#xD;
&#xD;
          -  Current or recent history (within 12 months) of drug or alcohol abuse.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Fertile women (defined as those who are not surgically sterile, are not &gt;1 year&#xD;
             post-menopausal or who are not currently using or complying with a medically approved&#xD;
             method of contraception). Lubiprostone has not been studied in pregnant women and&#xD;
             should only be used during a pregnancy if the potential benefits justify the potential&#xD;
             risk to the fetus. Women should have a negative pregnancy test before beginning&#xD;
             treatment with lubiprostone and need to practice effective contraceptive measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Ondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine PDCMDC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012 May 22;78(21):1650-4. doi: 10.1212/WNL.0b013e3182574f28. Epub 2012 May 9.</citation>
    <PMID>22573627</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <results_first_submitted>February 12, 2016</results_first_submitted>
  <results_first_submitted_qc>July 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2016</results_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Christine Hunter</investigator_full_name>
    <investigator_title>PDCMDC Research Manager</investigator_title>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amitiza</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were included if they had PD using standard criteria, were aged 35 to 85 years, and met the ROME II criteria19 and scored at least 10 on the ROME II constipation assessment. Excluded if they had any other identifiable cause of constipation, use of opioids, anticholinergic agents, or antacids containing magnesium or aluminum salts.</population>
      <group_list>
        <group group_id="B1">
          <title>Amitiza</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="8.1"/>
                    <measurement group_id="B2" value="70.1" spread="12.2"/>
                    <measurement group_id="B3" value="68.0" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="6.3"/>
                    <measurement group_id="B2" value="9.5" spread="6.3"/>
                    <measurement group_id="B3" value="9.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Study</title>
        <description>Global impression of change, stool diary, visual analog scale of improvement, UPDRS rating scale and constipation questionnaires. The primary efficacy data will be analyzed using Student's t-test with unequal variances as the difference from baseline in SBM comparing cases and controls, using last observation carried forward for missing data in the intent-to-treat population.</description>
        <time_frame>Baseline to end of study</time_frame>
        <population>A marked or very marked clinical global improvement.&#xD;
Ondo WG et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012 May 22; 78:1650. - See more at: http://www.jwatch.org/jn201205290000006/2012/05/29/lubiprostone-constipation-parkinson-disease#sthash.ggWrS7Vq.dpuf</population>
        <group_list>
          <group group_id="O1">
            <title>Amitiza</title>
            <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study</title>
          <description>Global impression of change, stool diary, visual analog scale of improvement, UPDRS rating scale and constipation questionnaires. The primary efficacy data will be analyzed using Student's t-test with unequal variances as the difference from baseline in SBM comparing cases and controls, using last observation carried forward for missing data in the intent-to-treat population.</description>
          <population>A marked or very marked clinical global improvement.&#xD;
Ondo WG et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012 May 22; 78:1650. - See more at: http://www.jwatch.org/jn201205290000006/2012/05/29/lubiprostone-constipation-parkinson-disease#sthash.ggWrS7Vq.dpuf</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amitiza</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=27) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>LUBIPROSTONE: Subjects will be randomized into placebo and study groups. Half of the study group (N=27) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine Hunter</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-6556</phone>
      <email>chunter@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

